- WKN: 566480
- ISIN: DE0005664809
- Land: Germany
Nachricht vom 24.06.2020 | 13:09
EVOTEC, SAMSARA BIOCAPITAL, AND KCK LAUNCH AUTOBAHN LABS
DGAP-News: Evotec SE
/ Key word(s): Alliance
Hamburg, Germany, and Palo Alto, USA, 24 June 2020: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), Samsara BioCapital, a leading life sciences investment firm, and KCK Ltd., a family investment fund, today announced the launch of Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyse early-stage drug discovery and development. Autobahn Labs also announced today a first-in-kind strategic collaboration with UCLA Technology Development Group ("UCLA TDG") to identify and advance the most promising areas of scientific research with the greatest potential for patient therapies.
"Autobahn Labs was created to be a catalyst for translational research, working with academic scientists and institutions to design and execute an accelerated path to deliver transformational new therapies," said Thomas Novak, PhD, Chief Scientific Officer of Autobahn Labs. "We are very excited to partner with UCLA, a university with a premier reputation for innovation in the life sciences, to realise the potential of that innovation for patients."
Built on a model of long-term partnership and collaboration, Autobahn Labs invests earlier than traditional venture capital, providing intellectual, financial and physical capital to efficiently and effectively advance new scientific discoveries from novel concept to pre-clinical drug candidate. Working in partnership with leading scientists and university tech transfer offices, the incubator identifies and de-risks early-stage research projects with significant therapeutic potential. Autobahn Labs creates jointly-owned new companies and invests up to $ 5 M per project. This model provides Principal Investigators with scientific and operational strategy as well as direct and immediate access to Evotec's state-of-the-art drug discovery and development technologies and capabilities.
"Autobahn Labs is a one-of-a-kind incubator that builds on the well-established foundation of our model of academic partnership programs, to support multiple academic institutions," said Dr Werner Lanthaler, Chief Executive Officer of Evotec. "Providing both funding and access to a powerful drug development platform, Autobahn Labs will be able to efficiently translate the ground-breaking research of leading academic institutions into medical progress to benefit patients with unmet medical need. We are very glad about our first partnership with the internationally renowned UCLA."
"Many of the most important advances in medicine were born in university labs," said Srinivas Akkaraju, MD, PhD, Managing General Partner, Samsara BioCapital. "While government funding and grants support basic research, there are limited resources available for translational research, particularly in the early stages. Autobahn Labs is investing early with a long-term perspective and a strong commitment to each program's success."
"UCLA TDG's mission is centred on innovation, research, teaching and entrepreneurship to benefit society," said Amir Naiberg, Associate Vice Chancellor, CEO & President of UCLA Technology Development Group. "TDG is exploring new models for Tech Transfer, this novel strategic collaboration with Autobahn Labs allows us to partner with industry experts earlier than ever before. We believe this will enable us to accelerate the transformation of our early scientific research into new drugs."
About Evotec's BRIDGE model: Partnering to accelerate innovation
ABOUT AUTOBAHN LABS
|Manfred Eigen Campus / Essener Bogen 7|
|Phone:||+49 (0)40 560 81-0|
|Fax:||+49 (0)40 560 81-222|
|Listed:||Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1077125|
|End of News||DGAP News Service|
Anleihe der German Real Estate Capital S.A. stark überdurchschnittlich attraktiv
Die Anleihe der German Real Estate Capital S.A. weist aktuell eine Effektivverzinsung von ca. 14 % auf. Da es sich hier quasi um eine Immobilien-Anleihe handelt, ist das Anleiherisiko überschaubar. Insgesamt verfügt die German Real Estate-Gruppe über 6 Objekte, 24 Bestands- und 22 Handelsobjekte, womit eine Kombination aus stetigen Einnahmen und attraktiven Entwicklerrenditen erreicht wird. Wir stufen die Anleihe als stark überdurchschnittlich attraktiv ein.
Der AKTIONÄR News
07. August 18:42 DAX, Dow & Co mit starker Woche – T-Mobile US und Biogen ...
07. August 15:32 AKTIONÄR-Tipp Nautilus: Stark wie Arnie
07. August 15:07 Ballard Power: Das ist der Grund für die Minirallye
07. August 14:30 Wirecard: Ein übler Verdacht
News im Fokus
Henkel AG & Co. KGaA: Henkel mit robuster Geschäftsentwicklung trotz starker Belastungen durch COVID-19-Pandemie
06. August 2020, 07:34
Webcast Q2 Results 2020
14. August 2020
Original-Research: Adler Modemärkte AG (von Sphene Capital GmbH): Buy
07. August 2020